查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1393484

全球乳癌治疗药物市场－产业趋势与预测（截至2030年）

Global Breast Cancer Drugs Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 300 Pages | 商品交期: 请询问到货日

价格

全球乳癌治疗市场规模将从2022年的302.4754亿美元增加至2030年的559.9657亿美元，预计2023-2030年的复合年增长率为8.2%。

本报告针对全球乳癌治疗药物市场进行研究分析，提供产业趋势与预测、促进与抑制因素、公司动态等资讯。

目录

第 1 章简介

第 2 章市场区隔

第 3 章执行摘要

第 4 章重要考量

  • 波特五力分析
  • PESTEL 分析
  • 流行病学
  • 管道分析

第 5 章规定

第 6 章市场概论

  • 促进因素
    • 乳癌治疗相关药物的进展
    • 各国的乳癌发生率不断上升
    • 乳癌标靶治疗领域不断取得进展
    • 在乳癌治疗中越来越多地使用荷尔蒙疗法
    • 增加与乳癌相关的筛检项目
  • 抑制因素
    • 与癌症治疗相关的药物成本不断增加
    • 对副作用和相容性的担忧
  • 机会
    • 癌症研究的政府措施和其他资金来源
    • 将人工智慧融入药物开发
    • 使用辅助治疗
  • 作业
    • 与化疗相关的併发症
    • 缺乏乳癌的早期发现

第 7 章全球乳癌治疗市场：依产品类型

  • 摘要
  • 医学
    • ANASTROZOLE (ARIMIDEX) 80
    • CYCLOPHOSPHAMIDE (CYTOXAN) 80
    • EXEMESTANE (AROMASIN) 80
    • LETROZOLE (FEMARA) 80
    • 其他
  • 化疗
    • FLUOROURACIL 81
    • METHOTREXATE 81
    • PACLITAXEL 81
    • EPIRUBICIN 81
    • DOCETAXEL 82
    • 其他
  • 放射治疗
  • 标靶治疗
    • PEMBROLIZUMAB 83
    • OLAPARIB 83
    • LAPROTRECTINIB 83
    • ENTRECTINIB 83
    • 其他
  • 其他

第 8 章全球乳癌治疗药物市场：依阶段

  • 摘要
  • 第一阶段
  • 第二阶段
  • 第零阶段
  • 第三阶段
  • 第四阶段

第 9 章全球乳癌治疗市场：依药物类型

  • 摘要
  • 品牌
  • 通用

第 10 章全球乳癌治疗药物市场：依年龄组别划分

  • 摘要
  • 老人
  • 成人

第 11 章全球乳癌治疗药物市场：依癌症类型划分

  • 摘要
  • 浸润性乳管癌 (IDC)
  • 浸润性小叶癌 (ILC)
  • 发炎性乳癌
  • 佩吉特乳头病
  • 乳房血管肉瘤
  • 乳房叶状肿瘤
  • 原位乳癌
  • 乳管原位癌 (DCIS)
  • 小叶原位癌 (LCIS)
  • 转移性乳癌
  • 其他

第 12 章全球乳癌治疗药物市场：依给药途径划分

  • 摘要
  • 静脉
  • 口服

第 13 章全球乳癌治疗市场：依最终使用者划分

  • 摘要
  • 医院
  • 癌症中心
  • 专科诊所
  • 其他

第 14 章全球乳癌治疗市场：依销售管道划分

  • 摘要
  • 医院药房
  • 零售药局
  • 网路药局

第 15 章全球乳癌治疗市场：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 瑞士
    • 比利时
    • 荷兰
    • 俄罗斯
    • 土耳其
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 澳大利亚
    • 韩国
    • 中国
    • 印度
    • 泰国
    • 印尼
    • 马来西亚
    • 新加坡
    • 菲律宾
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 南美洲其他地区
  • 中东/非洲
    • 南非
    • 埃及
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 其他中东/非洲

第 16 章全球乳癌治疗市场：公司状况

  • 公司股票分析：全球

第 17 章北美乳癌治疗市场：公司状况

  • 公司股票分析：北美

第 18 章欧洲乳癌治疗市场：公司状况

  • 公司股票分析：欧洲

第 19 章亚太乳癌治疗市场：企业状况

  • 公司股票分析：亚太地区

第 20 章 SWOT分析

第 21 章公司简介

  • F. HOFFMANN-LA ROCHE LTD
  • PFIZER INC.
  • ASTRAZENECA
  • NOVARTIS AG
  • ELI LILLY AND COMPANY
  • ABBVIE, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • EISAI CO., LTD
  • KYOWA KIRIN CO., LTD
  • MERCK & CO., INC.
  • MACROGENICS, INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • VIATRIS INC
  • GILEAD SCIENCES, INC
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

第 22 章调查

第 23 章相关报告

The global breast cancer drugs market is expected to reach USD 55,996.57 million by 2030 from USD 30,247.54 million in 2022, growing at a CAGR of 8.2% during the forecast period of 2023 to 2030.

Market Segmentation

Global Breast Cancer Drugs Market, By Product Type (Medication, Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), Cancer Type (Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), Inflammatory Breast Cancer, Paget's Disease of the Nipple, Angiosarcoma of the Breast, Phyllodes Tumors of the Breast, Non-Invasive (In-situ) Types of Breast Cancer, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), Metastatic Breast Cancer, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Drug Type (Generic and Branded), Age Group (Geriatric and Adults), Route of Administration (Oral and Intravenous), End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Breast Cancer Drugs Market Dynamics

  • Driver
  • Advancement in drugs associated with breast cancer treatment
  • Restraint
  • Rising cost of drugs associated with cancer treatment
  • Opportunity
  • Government initiatives and other funding sources for cancer research

Market Players

Some of the major market players operating in the global breast cancer drugs market are:

  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • AstraZeneca
  • Novartis AG
  • Lilly
  • Merck & Co., Inc.
  • Sanofi
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Mylan N.V. (A Subsidiary of Viatris Inc.)
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd.
  • MacroGenics, Inc.
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.

TABLE OF CONTENTS

1 INTRODUCTION 33

  • 1.1 OBJECTIVES OF THE STUDY 33
  • 1.2 MARKET DEFINITION 33
  • 1.3 OVERVIEW OF GLOBAL BREAST CANCER DRUGS MARKET 33
  • 1.4 CURRENCY AND PRICING 35
  • 1.5 LIMITATIONS 35
  • 1.6 MARKETS COVERED 35

2 MARKET SEGMENTATION 38

  • 2.1 MARKETS COVERED 38
  • 2.2 GEOGRAPHICAL SCOPE 39
  • 2.3 YEARS CONSIDERED FOR THE STUDY 40
  • 2.4 CURRENCY AND PRICING 40
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
  • 2.7 DBMR MARKET POSITION GRID 45
  • 2.8 MULTIVARIATE MODELLING 46
  • 2.9 PRODUCT TYPE LIFELINE CURVE 47
  • 2.10 MARKET END USER COVERAGE GRID 48
  • 2.11 SECONDARY SOURCES 49
  • 2.12 ASSUMPTIONS 49

3 EXECUTIVE SUMMARY 50

4 PREMIUM INSIGHTS 54

  • 4.1 PORTER'S FIVE FORCES 56
  • 4.2 PESTEL ANALYSIS 57
  • 4.3 EPIDEMIOLOGY 58
  • 4.4 PIPELINE ANALYSIS 59

5 REGULATIONS 60

6 MARKET OVERVIEW 64

  • 6.1 DRIVERS 66
    • 6.1.1 ADVANCEMENT IN DRUGS ASSOCIATED WITH BREAST CANCER TREATMENT 66
    • 6.1.2 INCREASING INCIDENCE OF BREAST CANCER ACROSS DIFFERENT COUNTRIES 67
    • 6.1.3 INCREASING DEVELOPMENT IN THE FIELD OF TARGETED THERAPY FOR BREAST CANCER 67
    • 6.1.4 INCREASING USAGE OF HORMONE THERAPY IN BREAST CANCER TREATMENT 68
    • 6.1.5 GROWING NUMBER OF SCREENING PROGRAMS RELATED TO BREAST CANCER 69
  • 6.2 RESTRAINTS 70
    • 6.2.1 RISING COST OF DRUGS ASSOCIATED WITH CANCER TREATMENT 70
    • 6.2.2 ADVERSE SIDE EFFECTS AND COMPATIBILITY CONCERNS 71
  • 6.3 OPPORTUNITIES 72
    • 6.3.1 GOVERNMENT INITIATIVES AND OTHER FUNDING SOURCES FOR CANCER RESEARCH 72
    • 6.3.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DEVELOPMENT 73
    • 6.3.3 USAGE OF ADJUVANT THERAPIES 74
  • 6.4 CHALLENGES 75
    • 6.4.1 COMPLICATIONS ASSOCIATED WITH CHEMOTHERAPY 75
    • 6.4.2 LACK IN EARLY DETECTION OF BREAST CANCER 75

7 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE 76

  • 7.1 OVERVIEW 77
  • 7.2 MEDICATION 79
    • 7.2.1 ANASTROZOLE (ARIMIDEX) 80
    • 7.2.2 CYCLOPHOSPHAMIDE (CYTOXAN) 80
    • 7.2.3 EXEMESTANE (AROMASIN) 80
    • 7.2.4 LETROZOLE (FEMARA) 80
    • 7.2.5 OTHERS 80
  • 7.3 CHEMOTHERAPY 80
    • 7.3.1 FLUOROURACIL 81
    • 7.3.2 METHOTREXATE 81
    • 7.3.3 PACLITAXEL 81
    • 7.3.4 EPIRUBICIN 81
    • 7.3.5 DOCETAXEL 82
    • 7.3.6 OTHERS 82
  • 7.4 RADIATION THERAPY 82
  • 7.5 TARGETED THERAPY 82
    • 7.5.1 PEMBROLIZUMAB 83
    • 7.5.2 OLAPARIB 83
    • 7.5.3 LAPROTRECTINIB 83
    • 7.5.4 ENTRECTINIB 83
    • 7.5.5 OTHERS 83
  • 7.6 OTHERS 84

8 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES 85

  • 8.1 OVERVIEW 86
  • 8.2 STAGE I 89
  • 8.3 STAGE II 89
  • 8.4 STAGE 0 90
  • 8.5 STAGE III 91
  • 8.6 STAGE IV 91

9 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE 92

  • 9.1 OVERVIEW 93
  • 9.2 BRANDED 95
  • 9.3 GENERIC 96

10 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP 97

  • 10.1 OVERVIEW 98
  • 10.2 GERIATRIC 100
  • 10.3 ADULTS 101

11 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE 102

  • 11.1 OVERVIEW 103
  • 11.2 INVASIVE DUCTAL CARCINOMA (IDC) 106
  • 11.3 INVASIVE LOBULAR CARCINOMA (ILC) 106
  • 11.4 INFLAMMATORY BREAST CANCER 107
  • 11.5 PAGET'S DISEASE OF THE NIPPLE 107
  • 11.6 ANGIOSARCOMA OF THE BREAST 108
  • 11.7 PHYLLODES TUMORS OF THE BREAST 108
  • 11.8 NONINVASIVE (IN-SITU) TYPES OF BREAST CANCER 109
  • 11.9 DUCTAL CARCINOMA IN SITU (DCIS) 109
  • 11.10 LOBULAR CARCINOM AIN SITU (LCIS) 110
  • 11.11 METASTATIC BREAST CANCER 110
  • 11.12 OTHERS 111

12 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 112

  • 12.1 OVERVIEW 113
  • 12.2 INTRAVENOUS 116
  • 12.3 ORAL 116

13 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER 117

  • 13.1 OVERVIEW 118
  • 13.2 HOSPITALS 121
  • 13.3 CANCER CENTERS 121
  • 13.4 SPECIALTY CLINICS 122
  • 13.5 OTHERS 122

 

14 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 123

  • 14.1 OVERVIEW 124
  • 14.2 HOSPITAL PHARMACY 127
  • 14.3 RETAIL PHARMACY 127
  • 14.4 ONLINE PHARMACY 127

15 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION 129

  • 15.1 OVERVIEW 130
  • 15.2 NORTH AMERICA 134
    • 15.2.1 U.S. 139
    • 15.2.2 CANADA 144
    • 15.2.3 MEXICO 149
  • 15.3 EUROPE 154
    • 15.3.1 GERMANY 159
    • 15.3.2 U.K. 162
    • 15.3.3 ITALY 165
    • 15.3.4 FRANCE 168
    • 15.3.5 SPAIN 171
    • 15.3.6 SWITZERLAND 174
    • 15.3.7 BELGIUM 177
    • 15.3.8 NETHERLANDS 180
    • 15.3.9 RUSSIA 183
    • 15.3.10 TURKEY 186
    • 15.3.11 REST OF EUROPE 189
  • 15.4 ASIA-PACIFIC 190
    • 15.4.1 JAPAN 194
    • 15.4.2 AUSTRALIA 197
    • 15.4.3 SOUTH KOREA 200
    • 15.4.4 CHINA 203
    • 15.4.5 INDIA 206
    • 15.4.6 THAILAND 209
    • 15.4.7 INDONESIA 212
    • 15.4.8 MALAYSIA 215
    • 15.4.9 SINGAPORE 218
    • 15.4.10 PHILIPPINES 221
    • 15.4.11 REST OF ASIA-PACIFIC 224

 

  • 15.5 SOUTH AMERICA 225
    • 15.5.1 ARGENTINA 229
    • 15.5.2 BRAZIL 232
    • 15.5.3 REST OF SOUTH AMERICA 235
  • 15.6 MIDDLE EAST AND AFRICA 236
    • 15.6.1 SOUTH AFRICA 240
    • 15.6.2 EGYPT 243
    • 15.6.3 U.A.E. 246
    • 15.6.4 SAUDI ARABIA 249
    • 15.6.5 REST OF MIDDLE EAST AND AFRICA 252

16 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE 253

  • 16.1 COMPANY SHARE ANALYSIS: GLOBAL 253

17 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE 254

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 254

18 EUROPE BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE 255

  • 18.1 COMPANY SHARE ANALYSIS: EUROPE 255

19 ASIA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE 256

  • 19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 256

20 SWOT ANALYSIS 257

21 COMPANY PROFILES 258

  • 21.1 F. HOFFMANN-LA ROCHE LTD 258
    • 21.1.1 COMPANY SNAPSHOT 258
    • 21.1.2 REVENUE ANALYSIS 258
    • 21.1.3 COMAPANY SHARE ANALYSIS 259
    • 21.1.4 PRODUCT PORTFOLIO 259
    • 21.1.5 RECENT DEVELOPMENTS 260
  • 21.2 PFIZER INC. 262
    • 21.2.1 COMPANY SNAPSHOT 262
    • 21.2.2 REVENUE ANALYSIS 262
    • 21.2.3 COMAPANY SHARE ANALYSIS 263
    • 21.2.4 PRODUCT PORTFOLIO 263
    • 21.2.5 RECENT DEVELOPMENTS 264
  • 21.3 ASTRAZENECA 265
    • 21.3.1 COMPANY SNAPSHOT 265
    • 21.3.2 REVENUE ANALYSIS 265
    • 21.3.3 COMAPANY SHARE ANALYSIS 266
    • 21.3.4 PRODUCT PORTFOLIO 266
    • 21.3.5 RECENT DEVELOPMENT 267
  • 21.4 NOVARTIS AG 268
    • 21.4.1 COMPANY SNAPSHOT 268
    • 21.4.2 REVENUE ANALYSIS 268
    • 21.4.3 COMAPANY SHARE ANALYSIS 269
    • 21.4.4 PRODUCT PORTFOLIO 269
    • 21.4.5 RECENT DEVELOPMENT 270
  • 21.5 ELI LILLY AND COMPANY 271
    • 21.5.1 COMPANY SNAPSHOT 271
    • 21.5.2 REVENUE ANALYSIS 272
    • 21.5.3 COMAPANY SHARE ANALYSIS 272
    • 21.5.4 PRODUCT PORTFOLIO 273
    • 21.5.5 RECENT DEVELOPMENTS 273
  • 21.6 ABBVIE, INC. 274
    • 21.6.1 COMPANY SNAPSHOT 274
    • 21.6.2 REVENUE ANALYSIS 274
    • 21.6.3 PRODUCT PORTFOLIO 275
    • 21.6.4 RECENT DEVELOPMENT 275
  • 21.7 BRISTOL-MYERS SQUIBB COMPANY 276
    • 21.7.1 COMPANY SNAPSHOT 276
    • 21.7.2 REVENUE ANALYSIS 276
    • 21.7.3 PRODUCT PORTFOLIO 277
    • 21.7.4 RECENT DEVELOPMENT 277
  • 21.8 EISAI CO., LTD 278
    • 21.8.1 COMPANY SNAPSHOT 278
    • 21.8.2 REVENUE ANALYSIS 278
    • 21.8.3 PRODUCT PORTFOLIO 279
    • 21.8.4 RECENT DEVELOPMENT 279
  • 21.9 KYOWA KIRIN CO., LTD 280
    • 21.9.1 COMPANY SNAPSHOT 280
    • 21.9.2 REVENUE ANALYSIS 280
    • 21.9.3 PRODUCT PORTFOLIO 281
    • 21.9.4 RECENT DEVELOPMENT 281
  • 21.10 MERCK & CO., INC. 282
    • 21.10.1 COMPANY SNAPSHOT 282
    • 21.10.2 REVENUE ANALYSIS 282
    • 21.10.3 PRODUCT PORTFOLIO 283
    • 21.10.4 RECENT DEVELOPMENT 283

 

  • 21.11 MACROGENICS, INC. 284
    • 21.11.1 COMPANY SNAPSHOT 284
    • 21.11.2 REVENUE ANALYSIS 284
    • 21.11.3 PRODUCT PORTFOLIO 285
    • 21.11.4 RECENT DEVELOPMENT 285
  • 21.12 SANOFI 286
    • 21.12.1 COMPANY SNAPSHOT 286
    • 21.12.2 REVENUE ANALYSIS 286
    • 21.12.3 PRODUCT PORTFOLIO 287
    • 21.12.4 RECENT DEVELOPMENTS 287
  • 21.13 TEVA PHARMACEUTICAL INDUSTRIES LTD 288
    • 21.13.1 COMPANY SNAPSHOT 288
    • 21.13.2 REVENUE ANALYSIS 288
    • 21.13.3 PRODUCT PORTFOLIO 289
    • 21.13.4 RECENT DEVELOPMENT 289
  • 21.14 VIATRIS INC 290
    • 21.14.1 COMPANY SNAPSHOT 290
    • 21.14.2 REVENUE ANALYSIS 290
    • 21.14.3 PRODUCT PORTFOLIO 291
    • 21.14.4 RECENT DEVELOPMENT 291
  • 21.15 GILEAD SCIENCES, INC 292
    • 21.15.1 COMPANY SNAPSHOT 292
    • 21.15.2 REVENUE ANALYSIS 292
    • 21.15.3 PRODUCT PORTFOLIO 293
    • 21.15.4 RECENT DEVELOPMENT 293
  • 21.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED 294
    • 21.16.1 COMPANY SNAPSHOT 294
    • 21.16.2 REVENUE ANALYSIS 294
    • 21.16.3 PRODUCT PORTFOLIO 295
    • 21.16.4 RECENT DEVELOPMENT 295

22 QUESTIONNAIRE 296

23 RELATED REPORTS 300

LIST OF TABLES

  • TABLE 1 GLOBAL BREAST CANCER DRUGS MARKET, PIPELINE ANALYSIS 59
  • TABLE 2 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 79
  • TABLE 3 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 79
  • TABLE 4 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 80
  • TABLE 5 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 6 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 7 GLOBAL RADIATION THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 8 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 9 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 83
  • TABLE 10 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 11 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES, 2022-2030 (USD MILLION) 88
  • TABLE 12 GLOBAL STAGE I IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 13 GLOBAL STAGE II IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 14 GLOBAL STAGE 0 IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 15 GLOBAL STAGE III IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 16 GLOBAL STAGE IV IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
  • TABLE 17 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 18 GLOBAL BRANDED IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 19 GLOBAL GENERIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 20 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 100
  • TABLE 21 GLOBAL GERIATRIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 22 GLOBAL ADULTS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
  • TABLE 23 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 24 GLOBAL INVASIVE DUCTAL CARCINOMA (IDC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 25 GLOBAL INVASIVE LOBULAR CARCINOMA (ILC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 26 GLOBAL INFLAMMATORY BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
  • TABLE 27 GLOBAL PAGET'S DISEASE OF THE NIPPLE IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
  • TABLE 28 GLOBAL ANGIOSARCOMA OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
  • TABLE 29 GLOBAL PHYLLODES TUMORS OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
  • TABLE 30 GLOBAL NONINVASIVE (IN SITU) TYPES OF BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 31 GLOBAL DUCTAL CARCINOMA IN SITU (DCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
  • TABLE 32 GLOBAL LOBULAR CARCINOMA IN SITU (LCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 33 GLOBAL METASTATIC BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
  • TABLE 34 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
  • TABLE 35 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 115
  • TABLE 36 GLOBAL INTRAVENOUS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 37 GLOBAL ORAL IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 38 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 120
  • TABLE 39 GLOBAL HOSPITALS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 40 GLOBAL CANCER CENTERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
  • TABLE 41 GLOBAL SPECIALTY CLINICS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
  • TABLE 42 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
  • TABLE 43 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 126
  • TABLE 44 GLOBAL HOSPITAL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 45 GLOBAL RETAIL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 46 GLOBAL ONLINE PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 47 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 48 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 134
  • TABLE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 50 NORTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 51 NORTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 52 NORTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 53 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 136
  • TABLE 54 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 137
  • TABLE 55 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 56 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 137
  • TABLE 57 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 138
  • TABLE 58 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 138
  • TABLE 59 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
  • TABLE 60 U.S. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 61 U.S. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 62 U.S. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 63 U.S. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 64 U.S. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 65 U.S. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 141
  • TABLE 66 U.S. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 67 U.S. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 142
  • TABLE 68 U.S. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 142
  • TABLE 69 U.S. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 142
  • TABLE 70 U.S. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 143
  • TABLE 71 CANADA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 72 CANADA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 73 CANADA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 74 CANADA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 75 CANADA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 76 CANADA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 146
  • TABLE 77 CANADA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 78 CANADA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 147
  • TABLE 79 CANADA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 147
  • TABLE 80 CANADA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
  • TABLE 81 CANADA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
  • TABLE 82 MEXICO BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 83 MEXICO MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 84 MEXICO CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 85 MEXICO TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 86 MEXICO BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 87 MEXICO BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 151
  • TABLE 88 MEXICO BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 89 MEXICO BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 152
  • TABLE 90 MEXICO BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 152
  • TABLE 91 MEXICO BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 152
  • TABLE 92 MEXICO BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 153
  • TABLE 93 EUROPE BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 154
  • TABLE 94 EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 95 EUROPE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 96 EUROPE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 97 EUROPE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 98 EUROPE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 99 EUROPE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 156
  • TABLE 100 EUROPE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 101 EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 157
  • TABLE 102 EUROPE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 157
  • TABLE 103 EUROPE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 157
  • TABLE 104 EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
  • TABLE 105 GERMANY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 106 GERMANY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 107 GERMANY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 108 GERMANY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 109 GERMANY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 110 GERMANY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 160
  • TABLE 111 GERMANY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 112 GERMANY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 161
  • TABLE 113 GERMANY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 161
  • TABLE 114 GERMANY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 161
  • TABLE 115 GERMANY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 161
  • TABLE 116 U.K. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 117 U.K. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 118 U.K. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 119 U.K. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 120 U.K. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 121 U.K. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 163
  • TABLE 122 U.K. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 123 U.K. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 164
  • TABLE 124 U.K. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 164
  • TABLE 125 U.K. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 164
  • TABLE 126 U.K. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 164
  • TABLE 127 ITALY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 128 ITALY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 129 ITALY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 130 ITALY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 131 ITALY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 166
  • TABLE 132 ITALY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 166
  • TABLE 133 ITALY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 167
  • TABLE 134 ITALY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 167
  • TABLE 135 ITALY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 167
  • TABLE 136 ITALY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 167
  • TABLE 137 ITALY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 167
  • TABLE 138 FRANCE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 139 FRANCE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 140 FRANCE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 168
  • TABLE 141 FRANCE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 142 FRANCE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 143 FRANCE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 169
  • TABLE 144 FRANCE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 145 FRANCE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 170
  • TABLE 146 FRANCE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 170
  • TABLE 147 FRANCE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 170
  • TABLE 148 FRANCE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 170
  • TABLE 149 SPAIN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 150 SPAIN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 151 SPAIN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 152 SPAIN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 153 SPAIN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 154 SPAIN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 172
  • TABLE 155 SPAIN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 156 SPAIN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 173
  • TABLE 157 SPAIN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 173
  • TABLE 158 SPAIN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 173
  • TABLE 159 SPAIN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 173
  • TABLE 160 SWITZERLAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 161 SWITZERLAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 162 SWITZERLAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 174
  • TABLE 163 SWITZERLAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 164 SWITZERLAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 165 SWITZERLAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 175
  • TABLE 166 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 167 SWITZERLAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 176
  • TABLE 168 SWITZERLAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 176
  • TABLE 169 SWITZERLAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 176
  • TABLE 170 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
  • TABLE 171 BELGIUM BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 172 BELGIUM MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 173 BELGIUM CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 174 BELGIUM TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 175 BELGIUM BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 176 BELGIUM BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 178
  • TABLE 177 BELGIUM BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 178 BELGIUM BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 179
  • TABLE 179 BELGIUM BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 179
  • TABLE 180 BELGIUM BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 179
  • TABLE 181 BELGIUM BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 179
  • TABLE 182 NETHERLANDS BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 183 NETHERLANDS MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 184 NETHERLANDS CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 180
  • TABLE 185 NETHERLANDS TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 186 NETHERLANDS BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 181
  • TABLE 187 NETHERLANDS BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 181
  • TABLE 188 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 189 NETHERLANDS BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 182
  • TABLE 190 NETHERLANDS BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 182
  • TABLE 191 NETHERLANDS BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 182
  • TABLE 192 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 182
  • TABLE 193 RUSSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 194 RUSSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 195 RUSSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 183
  • TABLE 196 RUSSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 197 RUSSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 198 RUSSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 184
  • TABLE 199 RUSSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 200 RUSSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 185
  • TABLE 201 RUSSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 185
  • TABLE 202 RUSSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 185
  • TABLE 203 RUSSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 185
  • TABLE 204 TURKEY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 205 TURKEY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 206 TURKEY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 207 TURKEY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 208 TURKEY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 209 TURKEY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 187
  • TABLE 210 TURKEY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 211 TURKEY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 188
  • TABLE 212 TURKEY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 188
  • TABLE 213 TURKEY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 188
  • TABLE 214 TURKEY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 188
  • TABLE 215 REST OF EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 216 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 190
  • TABLE 217 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 218 ASIA-PACIFIC MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 219 ASIA-PACIFIC CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 220 ASIA-PACIFIC TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 221 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 222 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 192
  • TABLE 223 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 224 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 193
  • TABLE 225 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 193
  • TABLE 226 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 193
  • TABLE 227 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 193
  • TABLE 228 JAPAN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 194
  • TABLE 229 JAPAN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 194
  • TABLE 230 JAPAN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 194
  • TABLE 231 JAPAN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 232 JAPAN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 233 JAPAN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 195
  • TABLE 234 JAPAN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 235 JAPAN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 196
  • TABLE 236 JAPAN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 196
  • TABLE 237 JAPAN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 196
  • TABLE 238 JAPAN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 196
  • TABLE 239 AUSTRALIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 240 AUSTRALIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 241 AUSTRALIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 242 AUSTRALIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 243 AUSTRALIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 244 AUSTRALIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 198
  • TABLE 245 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 199
  • TABLE 246 AUSTRALIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 199
  • TABLE 247 AUSTRALIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 199
  • TABLE 248 AUSTRALIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 199
  • TABLE 249 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 199
  • TABLE 250 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 251 SOUTH KOREA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 252 SOUTH KOREA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 253 SOUTH KOREA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 254 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 255 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 201
  • TABLE 256 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 257 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 202
  • TABLE 258 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 202
  • TABLE 259 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 202
  • TABLE 260 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 202
  • TABLE 261 CHINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 262 CHINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 263 CHINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 203
  • TABLE 264 CHINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 204
  • TABLE 265 CHINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 204
  • TABLE 266 CHINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 204
  • TABLE 267 CHINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 205
  • TABLE 268 CHINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 205
  • TABLE 269 CHINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 205
  • TABLE 270 CHINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 205
  • TABLE 271 CHINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 205
  • TABLE 272 INDIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 273 INDIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 274 INDIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 206
  • TABLE 275 INDIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 207
  • TABLE 276 INDIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 207
  • TABLE 277 INDIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 207
  • TABLE 278 INDIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 208
  • TABLE 279 INDIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 208
  • TABLE 280 INDIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 208
  • TABLE 281 INDIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 208
  • TABLE 282 INDIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 208
  • TABLE 283 THAILAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 209
  • TABLE 284 THAILAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 209
  • TABLE 285 THAILAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 209
  • TABLE 286 THAILAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 210
  • TABLE 287 THAILAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 210
  • TABLE 288 THAILAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 210
  • TABLE 289 THAILAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 211
  • TABLE 290 THAILAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 211
  • TABLE 291 THAILAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 211
  • TABLE 292 THAILAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 211
  • TABLE 293 THAILAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 211
  • TABLE 294 INDONESIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 295 INDONESIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 296 INDONESIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 212
  • TABLE 297 INDONESIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 298 INDONESIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 213
  • TABLE 299 INDONESIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 213
  • TABLE 300 INDONESIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 214
  • TABLE 301 INDONESIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 214
  • TABLE 302 INDONESIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 214
  • TABLE 303 INDONESIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 214
  • TABLE 304 INDONESIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 214
  • TABLE 305 MALAYSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 215
  • TABLE 306 MALAYSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 215
  • TABLE 307 MALAYSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 215
  • TABLE 308 MALAYSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 216
  • TABLE 309 MALAYSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 216
  • TABLE 310 MALAYSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 216
  • TABLE 311 MALAYSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 217
  • TABLE 312 MALAYSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 217
  • TABLE 313 MALAYSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 217
  • TABLE 314 MALAYSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 217
  • TABLE 315 MALAYSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 217
  • TABLE 316 SINGAPORE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 317 SINGAPORE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 318 SINGAPORE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 218
  • TABLE 319 SINGAPORE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 320 SINGAPORE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 219
  • TABLE 321 SINGAPORE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 219
  • TABLE 322 SINGAPORE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 220
  • TABLE 323 SINGAPORE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 220
  • TABLE 324 SINGAPORE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 220
  • TABLE 325 SINGAPORE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 220
  • TABLE 326 SINGAPORE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 220
  • TABLE 327 PHILIPPINES BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 328 PHILIPPINES MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 329 PHILIPPINES CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 330 PHILIPPINES TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 222
  • TABLE 331 PHILIPPINES BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 222
  • TABLE 332 PHILIPPINES BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 222
  • TABLE 333 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 334 PHILIPPINES BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 223
  • TABLE 335 PHILIPPINES BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 223
  • TABLE 336 PHILIPPINES BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 223
  • TABLE 337 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 223
  • TABLE 338 REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 339 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 225
  • TABLE 340 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 225
  • TABLE 341 SOUTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 225
  • TABLE 342 SOUTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 226
  • TABLE 343 SOUTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 226
  • TABLE 344 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 226
  • TABLE 345 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 227
  • TABLE 346 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 227
  • TABLE 347 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 227
  • TABLE 348 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 227
  • TABLE 349 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 228
  • TABLE 350 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 228
  • TABLE 351 ARGENTINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 352 ARGENTINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 353 ARGENTINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 229
  • TABLE 354 ARGENTINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 230
  • TABLE 355 ARGENTINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 230
  • TABLE 356 ARGENTINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 230
  • TABLE 357 ARGENTINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 231
  • TABLE 358 ARGENTINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 231
  • TABLE 359 ARGENTINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 231
  • TABLE 360 ARGENTINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 231
  • TABLE 361 ARGENTINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 231
  • TABLE 362 BRAZIL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 363 BRAZIL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 364 BRAZIL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 365 BRAZIL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 366 BRAZIL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 367 BRAZIL BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 233
  • TABLE 368 BRAZIL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 234
  • TABLE 369 BRAZIL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 234
  • TABLE 370 BRAZIL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 234
  • TABLE 371 BRAZIL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 234
  • TABLE 372 BRAZIL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 234
  • TABLE 373 REST OF SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 235
  • TABLE 374 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 236
  • TABLE 375 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 236
  • TABLE 376 MIDDLE EAST AND AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 236
  • TABLE 377 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 378 MIDDLE EAST AND AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 237
  • TABLE 379 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 238
  • TABLE 380 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 238
  • TABLE 381 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 238
  • TABLE 382 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 239
  • TABLE 383 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 239
  • TABLE 384 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 239
  • TABLE 385 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 239
  • TABLE 386 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 387 SOUTH AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 388 SOUTH AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 389 SOUTH AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 390 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 391 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 241
  • TABLE 392 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 393 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 242
  • TABLE 394 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 242
  • TABLE 395 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 242
  • TABLE 396 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 242
  • TABLE 397 EGYPT BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 243
  • TABLE 398 EGYPT MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 243
  • TABLE 399 EGYPT CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 243
  • TABLE 400 EGYPT TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 244
  • TABLE 401 EGYPT BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 244
  • TABLE 402 EGYPT BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 244
  • TABLE 403 EGYPT BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 404 EGYPT BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 245
  • TABLE 405 EGYPT BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 245
  • TABLE 406 EGYPT BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 245
  • TABLE 407 EGYPT BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 245
  • TABLE 408 U.A.E. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 409 U.A.E. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 410 U.A.E. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 411 U.A.E. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 247
  • TABLE 412 U.A.E. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 247
  • TABLE 413 U.A.E. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 247
  • TABLE 414 U.A.E. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 415 U.A.E. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 248
  • TABLE 416 U.A.E. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 248
  • TABLE 417 U.A.E. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 248
  • TABLE 418 U.A.E. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 248
  • TABLE 419 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 420 SAUDI ARABIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 421 SAUDI ARABIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 422 SAUDI ARABIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 423 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 424 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION) 250
  • TABLE 425 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 251
  • TABLE 426 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 251
  • TABLE 427 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 251
  • TABLE 428 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION) 251
  • TABLE 429 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 251
  • TABLE 430 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 252

LIST OF FIGURES

  • FIGURE 1 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION 38
  • FIGURE 2 GLOBAL BREAST CANCER DRUGS MARKET: DATA TRIANGULATION 41
  • FIGURE 3 GLOBAL BREAST CANCER DRUGS MARKET: DROC ANALYSIS 42
  • FIGURE 4 GLOBAL BREAST CANCER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 43
  • FIGURE 5 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 43
  • FIGURE 6 GLOBAL BREAST CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 44
  • FIGURE 7 GLOBAL BREAST CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 45
  • FIGURE 8 GLOBAL BREAST CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 48
  • FIGURE 9 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION 52
  • FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL BREAST CANCER DRUGS MARKET AND ASIA-PACIFIC REGION GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 53
  • FIGURE 11 RISING INCIDENCE OF BREAST CANCER IS DRIVING THE GROWTH OF GLOBAL BREAST CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 54
  • FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BREAST CANCER DRUGS MARKET IN 2023 & 2030 54
  • FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR BREAST CANCER DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 55
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BREAST CANCER DRUGS MARKET 65
  • FIGURE 15 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2022 77
  • FIGURE 16 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 78
  • FIGURE 17 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 78
  • FIGURE 18 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 79
  • FIGURE 19 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES , 2022 86
  • FIGURE 20 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, 2023-2030 (USD MILLION) 87
  • FIGURE 21 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, CAGR (2023-2030) 87
  • FIGURE 22 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, LIFELINE CURVE 88
  • FIGURE 23 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2022 93
  • FIGURE 24 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION) 94
  • FIGURE 25 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 94
  • FIGURE 26 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 95
  • FIGURE 27 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2022 98
  • FIGURE 28 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 99
  • FIGURE 29 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 99
  • FIGURE 30 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 100
  • FIGURE 31 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2022 103
  • FIGURE 32 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 104
  • FIGURE 33 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 104
  • FIGURE 34 GLOBAL BREAST CANCER DRUGS MARKET: BY T CANCER TYPE, LIFELINE CURVE 105
  • FIGURE 35 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 113
  • FIGURE 36 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION) 114
  • FIGURE 37 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 114
  • FIGURE 38 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 115
  • FIGURE 39 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2022 118
  • FIGURE 40 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION) 119
  • FIGURE 41 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 119
  • FIGURE 42 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 120
  • FIGURE 43 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 124
  • FIGURE 44 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 125
  • FIGURE 45 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 125
  • FIGURE 46 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 126
  • FIGURE 47 GLOBAL BREAST CANCER DRUGS MARKET: SNAPSHOT (2022) 131
  • FIGURE 48 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 253
  • FIGURE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 254
  • FIGURE 50 EUROPE BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 255
  • FIGURE 51 AISA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 256